CATALYST PHARMACEUTICALS, INC. — Director's Dealing 2025

Aug 28, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK: 0001369568
Period of Report: 2025-08-26

Reporting Person: Miller Steve (Chief Op. & Scientific Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-08-26	Common stock, par value $0.001 per share	M	115000	$2.24	Acquired	1064663	Direct
2025-08-26	Common stock, par value $0.001 per share	S	115000	$20.28	Disposed	949663	Direct
2025-08-27	Common stock, par value $0.001 per share	M	110000	$2.24	Acquired	1059663	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-08-26	Options to purchase common stock	$2.24	M	115000	Disposed	2025-12-19	Common Stock (115000)	Direct
2025-08-27	Options to purchase common stock	$2.24	M	110000	Disposed	2025-12-19	Common Stock (110000)	Direct

Footnotes

F1: Shares were sold on the open market to fund the exercise price and estimated taxes due from Reporting Person as a result of the exercise of the 225,000 stock options reported on Table II.

F2: Represents a weighted average sale price. Shares were sold in a range from $20.04 to $20.645 per share.

F3: Derivative Securities vested in three annual tranches beginning on December 18, 2019.